Zacks Investment Research
17 Sept 2026, 15:50 UTC · 1h ago
Verdict
Headline takes no side. We score RHHBY +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Roche announced that the phase III CELESTIMO study of Lunsumio plus Revlimid for relapsed or refractory follicular lymphoma met its primary endpoint of progression-free survival.
Newannounced September 17, 2026
More positive than 91% of claims this week
The CELESTIMO study serves as the confirmatory trial required to convert Lunsumio's accelerated approval for third-line or later follicular lymphoma into full approval.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
Roche intends to use the CELESTIMO data to support a new indication for Lunsumio in second-line or later follicular lymphoma.
Newannounced September 17, 2026
More positive than 65% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Roche announced that its phase III CELESTIMO study met its primary endpoint, showing significant improvement in progression-free survival.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
10h ago
−0.6%
Price is moving against the score
$54.80 vs $55.15 close before publication (Sep 16) · not market-adjusted
RHHBY chart →
